Drug profile · INN
clotrimazole
APO-CLOTRIMAZOLE 3 DAY CREAM
clotrimazole (APO-CLOTRIMAZOLE 3 DAY CREAM) is a cytochrome p450 51 inhibitor. Associated with Alphapharm Pty Ltd. Route of administration: topical. Current US regulatory status: approved.
Drug details — clotrimazole
- US status
- approved
- Class
- —
- Route
- TOPICAL
- Patents
- 0
- Programs
- 0
- Data quality
- 0.89
Quick answer
clotrimazole (APO-CLOTRIMAZOLE 3 DAY CREAM) is a cytochrome p450 51 inhibitor. Associated with Alphapharm Pty Ltd. Route of administration: topical. Current US regulatory status: approved.
Key facts
Mechanism of action
Cytochrome P450 51 inhibitor
Primary target: Lanosterol 14-alpha demethylase
Approval history
| Authority | Status | Date |
|---|---|---|
| FDA | approved | — |
| TGA | approved | — |
Related & competitor drugs
Frequently asked questions
What is clotrimazole?
clotrimazole (APO-CLOTRIMAZOLE 3 DAY CREAM) is a cytochrome p450 51 inhibitor. Associated with Alphapharm Pty Ltd. Route of administration: topical. Current US regulatory status: approved.
What is the brand name for clotrimazole?
APO-CLOTRIMAZOLE 3 DAY CREAM is a marketed brand name for clotrimazole. Check FDA Drugs@FDA for the current US label holder and prescribing information.
What is the US approval status of clotrimazole?
clotrimazole has approved status in the United States according to our Drugs@FDA-derived records. Verify on the official FDA label before clinical or commercial decisions.